Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 31, 2010 Brian Orelli	A Double-Digit Jump? For That? Isis' drug discovery license doesn't look too exciting to me.
The Motley Fool January 9, 2008 Brian Orelli	Genzyme Buys Into Antisense RNA -- Big Time Genzyme buys a piece of Isis' mipomersen at a wowser of a price.
The Motley Fool October 4, 2007 Billy Fisher	Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note.
The Motley Fool May 25, 2005 Brian Gorman	Another Deal for Isis Investors shouldn't get their hopes up over the drugmaker's latest collaboration.
The Motley Fool January 6, 2004 David Nierengarten	Isis' 2G Drug Shines Will Isis start making cents from anti-sense drugs?
The Motley Fool June 23, 2010 Brian Orelli	A Novel Drug Technology Worth Watching Regulus signs up another microRNA partner.
The Motley Fool September 14, 2007 Brian Orelli	J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note.
The Motley Fool April 9, 2008 Brian Orelli	Isis Ignited by Bristol-Myers Bristol-Myers Squibb selects an Isis-developed compound, triggering a milestone payment.
The Motley Fool May 20, 2009 Brian Orelli	Clinical Trial Positive, Stock Not So Much Isis and Genzyme hit a homer with their cholesterol drug, mipomersen, but they'll need another big play to win the game.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool April 18, 2008 Brian Orelli	Big Deal for Small RNAs Glaxo buys into Regulus' microRNA research.
The Motley Fool November 18, 2009 Brian Orelli	Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data.
The Motley Fool April 28, 2008 Brian Orelli	FDA Moves Isis' Finish Line The FDA tells drugmaker Isis it must complete cancer tests before submitting its marketing application.
The Motley Fool May 15, 2007 Mike Havrilla	Eyeing ISIS A robust pipeline and a promising cholesterol drug could benefit this pharmaceutical firm. Investors, take note.
The Motley Fool February 4, 2008 Brian Lawler	Genzyme Tells It Like It Is Genzyme shows some sparkle at investors' conference. Investors, take note.
The Motley Fool January 11, 2011 Brian Orelli	A Clear Drug-Development Path -- Times 2 The FDA throws a fork in the road for Isis and Genzyme.
The Motley Fool December 17, 2008 Brian Orelli	A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off.
The Motley Fool February 17, 2004 David Nierengarten	Antisense Making Sense? An update on Genasense, its future, and how the antisense marketplace is shaping up. The FDA has agreed to review the new drug applications.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool January 5, 2011 Brian Orelli	Pfizer Goes Back for Seconds Headed back for more from Santaris. The company is putting up just $14 million for expanded access to Santaris' LNA technology.
The Motley Fool July 8, 2008 Brian Orelli	Not Teva's Forte Teva Pharmaceutical's Copaxone for multiple sclerosis fails to show a benefit at double strength. Investors take note.
The Motley Fool August 5, 2010 Brian Orelli	Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
The Motley Fool June 22, 2010 Luke Timmerman	Regulus Therapeutics Forms $750M MicroRNA Deal With Sanofi The company has found its second big ally from Big Pharma.
The Motley Fool May 28, 2008 Brian Orelli	A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs.
The Motley Fool December 2, 2010 Brian Orelli	A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool February 11, 2010 Brian Orelli	A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.
The Motley Fool October 23, 2008 Brian Orelli	Glaxo to Competitors: You're Cheaper Than We Are This big pharma has cash and it plans to use it.
The Motley Fool December 17, 2007 Brian Lawler	Glaxo, Exelixis Trade Gifts Glaxo announces that it will take over development of a lead Exelixis drug.
The Motley Fool September 11, 2008 Brian Orelli	Glaxo's Not Gambling The pharmaceutical's deal for drug developer Cellzome is back-end loaded.
The Motley Fool January 9, 2009 Brian Orelli	Thanks for Nothing, FDA The Food and Drug Administration says there's still enough evidence that Merck and Schering-Plough's Vytorin works to warrant keeping patients on the drug.
The Motley Fool December 4, 2008 Brian Orelli	Poor Pozen It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen.
The Motley Fool November 15, 2007 Brian Orelli	Slowing the Cash Burn Bloody Nose Nastech plans to cut costs following Proctor& Gamble's drop of their osteoporosis drug. Investors, take note.
The Motley Fool November 22, 2011 Luke Timmerman	Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring Pfizer is making a new bet on a new drug to fight excessive scarring.
The Motley Fool February 12, 2009 Brian Orelli	Cruising, but Ready to Take Off Genzyme's in wait-and-see mode.
The Motley Fool February 9, 2006 Jason Mac Gurn	RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...
The Motley Fool June 14, 2007 Ryan Fuhrmann	Dueling Fools: GlaxoSmithKline Bear Rebuttal There are better opportunities to use short-term pain and establish positions in pharmaceuticals with better long-term potential.
The Motley Fool May 22, 2008 Brian Orelli	Merck Can't Achieve Anything The pharmaceutical cancels a troubled clinical trial.
The Motley Fool April 13, 2010 Brian Orelli	Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development.
The Motley Fool April 10, 2008 Brian Lawler	Glaxo Angers the FDA GlaxoSmithKline announces that the FDA has sent it a warning letter regarding its failure to meet certain post-marketing requirements for Avandia.
The Motley Fool December 18, 2008 Brian Orelli	A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis.
The Motley Fool December 31, 2009 Brian Orelli	Make Money Even When Drugs Fail Biotech growth potential without as much risk can come from innovations that help drugmakers discover new drugs.
The Motley Fool June 13, 2008 Brian Lawler	Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval.
The Motley Fool March 7, 2005 Brian Gorman	Glaxo in Hot Water Glaxo's problems with the FDA could have been avoided. Investors can only hope that the FDA is in a forgiving mood.
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool October 28, 2004 Bill Mann	Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year.
The Motley Fool April 21, 2009 Brian Orelli	Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply.
The Motley Fool January 21, 2010 Brian Orelli	The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments.
The Motley Fool September 20, 2007 Brian Orelli	A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors?
BusinessWeek November 27, 2006 Gene G. Marcial	ISIS Takes Heart From A Promising Drug ISIS Pharmaceuticals is a name to watch in the lucrative arena of cholesterol reduction.